Ost-müük FibroGen, Inc - FGEN CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Kauplemistingimused
| Hinnavahe | 0.23 | ||||||||
|
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.025457% | ||||||||
|
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.003235% | ||||||||
| Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
| Min kauplemise kogus | 1 | ||||||||
| Valuuta | USD | ||||||||
| Tagatis | 20% | ||||||||
| Aktsiabörs | United States of America | ||||||||
| Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
FibroGen Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Võtmestatistika
| Eelmine sulgemine* | 18.54 |
| Avatud* | 18.08 |
| Aastane muutus* | 91.12% |
| Päeva ulatus* | 16.53 - 18.08 |
| 52 nädala ulatus | 8.67-25.69 |
| Keskmine maht (10 päeva) | 1.03M |
| Keskmine maht (3 kuud) | 18.80M |
| Turukapitalisatsioon | 1.87B |
| P/E suhtarv | -100.00K |
| Ringluses olevad aktsiad | 97.58M |
| Tulu | 116.07M |
| EPS | -3.27 |
| Dividendid (% kasumist) | N/A |
| Beeta | 0.79 |
| Järgmine tuluaruande kuupäev | Aug 7, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
|---|---|---|---|---|---|---|
| Jun 6, 2023 | 18.54 | -0.46 | -2.42% | 19.00 | 19.14 | 18.53 |
| Jun 5, 2023 | 19.05 | 1.83 | 10.63% | 17.22 | 19.43 | 17.22 |
| Jun 2, 2023 | 17.79 | -0.94 | -5.02% | 18.73 | 19.05 | 17.34 |
| Jun 1, 2023 | 17.18 | 0.22 | 1.30% | 16.96 | 17.59 | 16.70 |
| May 31, 2023 | 17.16 | 0.15 | 0.88% | 17.01 | 17.61 | 16.72 |
| May 30, 2023 | 17.04 | 0.47 | 2.84% | 16.57 | 17.33 | 16.46 |
| May 26, 2023 | 16.65 | 0.03 | 0.18% | 16.62 | 16.80 | 16.33 |
| May 25, 2023 | 16.82 | 0.16 | 0.96% | 16.66 | 16.91 | 16.44 |
| May 24, 2023 | 16.90 | -0.05 | -0.29% | 16.95 | 17.33 | 16.51 |
| May 23, 2023 | 17.27 | 0.06 | 0.35% | 17.21 | 18.03 | 16.99 |
| May 22, 2023 | 17.16 | -0.14 | -0.81% | 17.30 | 18.02 | 16.96 |
| May 19, 2023 | 17.49 | -0.07 | -0.40% | 17.56 | 18.07 | 17.20 |
| May 18, 2023 | 17.53 | 0.01 | 0.06% | 17.52 | 17.89 | 17.29 |
| May 17, 2023 | 17.77 | 0.80 | 4.71% | 16.97 | 17.86 | 16.92 |
| May 16, 2023 | 17.40 | 0.25 | 1.46% | 17.15 | 17.51 | 17.08 |
| May 15, 2023 | 17.58 | 0.46 | 2.69% | 17.12 | 17.91 | 17.03 |
| May 12, 2023 | 17.31 | -0.11 | -0.63% | 17.42 | 17.66 | 17.09 |
| May 11, 2023 | 17.48 | -0.12 | -0.68% | 17.60 | 18.00 | 17.38 |
| May 10, 2023 | 17.65 | 0.25 | 1.44% | 17.40 | 17.84 | 17.17 |
| May 9, 2023 | 17.30 | 1.25 | 7.79% | 16.05 | 17.89 | 15.97 |
FibroGen, Inc Events
| Kellaaeg (UTC) (UTC) | Riik | Sündmus |
|---|---|---|
| Wednesday, June 7, 2023 | ||
| Kellaaeg (UTC) (UTC) 15:00 | Riik US
| Sündmus FibroGen Inc Annual Shareholders Meeting FibroGen Inc Annual Shareholders MeetingForecast -Previous - |
| Thursday, June 8, 2023 | ||
| Kellaaeg (UTC) (UTC) 18:30 | Riik US
| Sündmus FibroGen Inc at Jefferies Healthcare Conference FibroGen Inc at Jefferies Healthcare ConferenceForecast -Previous - |
| Monday, June 12, 2023 | ||
| Kellaaeg (UTC) (UTC) 18:20 | Riik US
| Sündmus FibroGen Inc at Goldman Sachs Healthcare Conference FibroGen Inc at Goldman Sachs Healthcare ConferenceForecast -Previous - |
| Friday, June 16, 2023 | ||
| Kellaaeg (UTC) (UTC) 15:00 | Riik US
| Sündmus FibroGen Inc Annual Shareholders Meeting FibroGen Inc Annual Shareholders MeetingForecast -Previous - |
| Monday, August 7, 2023 | ||
| Kellaaeg (UTC) (UTC) 10:59 | Riik US
| Sündmus Q2 2023 FibroGen Inc Earnings Release Q2 2023 FibroGen Inc Earnings ReleaseForecast -Previous - |
| Monday, November 6, 2023 | ||
| Kellaaeg (UTC) (UTC) 10:59 | Riik US
| Sündmus Q3 2023 FibroGen Inc Earnings Release Q3 2023 FibroGen Inc Earnings ReleaseForecast -Previous - |
- Aastas
- Kvartalis
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Kogutulu | 140.734 | 235.309 | 176.319 | 256.577 | 212.958 |
| Tulu | 140.734 | 235.309 | 176.319 | 256.577 | 212.958 |
| Kogu tegevuskulu | 441.759 | 523.839 | 368.199 | 345.891 | 299.651 |
| Müük/Üldine/admin kulud, kokku | 127.474 | 120.557 | 97.238 | 126.557 | 63.812 |
| Uuringud ja arendus | 296.791 | 387.043 | 252.924 | 209.265 | 235.839 |
| Tulud majandustegevusest | -301.025 | -288.53 | -191.88 | -89.314 | -86.693 |
| Intressitulud (kulu), muud tulud, neto | 6.156 | -2.153 | 3.151 | 12.672 | 0.577 |
| Netotulu enne makse | -294.869 | -290.683 | -188.729 | -76.642 | -86.116 |
| Netotulu pärast makse | -295.227 | -291.03 | -189.089 | -76.97 | -86.42 |
| Netotulu enne erikulusid | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Netotulu | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Arvestatav tulu, v a erikulud | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Arvestatav tulu, koos erikuludega | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Jaotamisele kuuluv netotulu | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Keskmine jaotamisele kuuluv aktsia kohta | 93.582 | 92.349 | 89.854 | 86.633 | 84.062 |
| Jaotatav EPS, v a erakorralised kulud | -3.13793 | -3.14051 | -2.10665 | -0.88846 | -1.02805 |
| Jaotamisele kuuluv normaal-EPS | -3.13793 | -3.14051 | -2.10665 | -0.88846 | -1.02805 |
| Erakorralised kulud kokku | |||||
| Kulud, Kokku | 20.28 | 12.871 | 8.869 | 1.147 | |
| Brutokasum | 120.454 | 222.438 | 167.45 | 255.43 | |
| Depreciation / Amortization | 0.587 | 4.639 | 10.369 | 10.307 | |
| Other Operating Expenses, Total | -3.373 | -1.271 | -1.201 | -1.385 | |
| Equity In Affiliates | 1.573 | 1.007 | -0.202 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Kogutulu | 36.161 | 34.367 | 15.735 | 29.806 | 60.827 |
| Tulu | 36.161 | 34.367 | 15.735 | 29.806 | 60.827 |
| Kulud, Kokku | 3.491 | 4.925 | 4.308 | 6.809 | 4.238 |
| Brutokasum | 32.67 | 29.442 | 11.427 | 22.997 | 56.589 |
| Kogu tegevuskulu | 112.252 | 100.519 | 109.392 | 108.03 | 123.82 |
| Müük/Üldine/admin kulud, kokku | 34.275 | 33.966 | 29.902 | 30.258 | 30.564 |
| Uuringud ja arendus | 74.486 | 61.628 | 75.182 | 70.963 | 89.018 |
| Other Operating Expenses, Total | |||||
| Tulud majandustegevusest | -76.091 | -66.152 | -93.657 | -78.224 | -62.993 |
| Intressitulud (kulu), muud tulud, neto | -1.336 | -0.195 | 1.714 | 5.058 | -0.419 |
| Netotulu enne makse | -77.427 | -66.347 | -91.943 | -73.166 | -63.412 |
| Netotulu pärast makse | -77.501 | -66.455 | -92.057 | -73.189 | -63.525 |
| Equity In Affiliates | 0.796 | 0.28 | 0.407 | 0.565 | 0.32 |
| Netotulu enne erikulusid | -76.705 | -66.175 | -91.65 | -72.624 | -63.205 |
| Netotulu | -76.705 | -66.175 | -91.65 | -72.624 | -63.205 |
| Arvestatav tulu, v a erikulud | -76.705 | -66.175 | -91.65 | -72.624 | -63.205 |
| Arvestatav tulu, koos erikuludega | -76.705 | -66.175 | -91.65 | -72.624 | -63.205 |
| Jaotamisele kuuluv netotulu | -76.705 | -66.175 | -91.65 | -72.624 | -63.205 |
| Keskmine jaotamisele kuuluv aktsia kohta | 94.691 | 94.035 | 93.767 | 93.475 | 93.043 |
| Jaotatav EPS, v a erakorralised kulud | -0.81006 | -0.70373 | -0.97742 | -0.77694 | -0.67931 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Jaotamisele kuuluv normaal-EPS | -0.81006 | -0.70373 | -0.97742 | -0.77694 | -0.67931 |
- Aastas
- Kvartalis
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 492.826 | 474.059 | 755.11 | 702.49 | 690.015 |
| Raha ja lühiajalised investeeringud | 422.008 | 405.19 | 686.537 | 533.757 | 621.402 |
| Cash | 135.819 | 111.422 | 88.046 | 40.715 | 38.783 |
| Raha ja ekvivalendid | 19.881 | 59.801 | 590.347 | 85.551 | 50.475 |
| Lühiajalised investeeringud | 266.308 | 233.967 | 8.144 | 407.491 | 532.144 |
| Laekumata arved, neto | 16.299 | 25.401 | 41.883 | 153.665 | 63.684 |
| Accounts Receivable - Trade, Net | 28.387 | 36.331 | 46.01 | 158.51 | 16.474 |
| Prepaid Expenses | 9.73 | 7.383 | 8.353 | 6.464 | 4.929 |
| Total Assets | 610.087 | 773.821 | 826.84 | 857.397 | 880.598 |
| Property/Plant/Equipment, Total - Net | 100.933 | 120.15 | 65.296 | 84.276 | 127.198 |
| Property/Plant/Equipment, Total - Gross | 253.644 | 252.362 | 199.305 | 195.752 | 192.397 |
| Accumulated Depreciation, Total | -152.711 | -132.212 | -134.009 | -111.476 | -65.199 |
| Long Term Investments | 9.409 | 171.621 | 2.972 | 61.118 | 55.82 |
| Other Long Term Assets, Total | 6.919 | 7.991 | 3.462 | 9.513 | 7.565 |
| Total Current Liabilities | 273.562 | 225.497 | 163.187 | 102.745 | 89.033 |
| Accounts Payable | 30.758 | 26.097 | 24.789 | 6.088 | 9.139 |
| Accrued Expenses | 229.639 | 180.356 | 104.384 | 83.816 | 66.123 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 13.129 | 19.033 | 21.684 | 0.49 | 13.771 |
| Total Liabilities | 631.534 | 564.675 | 404.662 | 341.262 | 371.399 |
| Total Long Term Debt | 17.054 | 17.616 | 44.088 | 55.531 | 113.955 |
| Long Term Debt | 16.917 | 17.613 | 18.697 | 16.78 | 16.798 |
| Capital Lease Obligations | 0.137 | 0.003 | 25.391 | 38.751 | 97.157 |
| Minority Interest | 19.967 | 19.967 | 19.271 | 19.271 | 19.271 |
| Other Liabilities, Total | 320.951 | 292.403 | 169.441 | 163.715 | 149.14 |
| Total Equity | -21.447 | 209.146 | 422.178 | 516.135 | 509.199 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.942 | 0.929 | 0.914 | 0.877 | 0.854 |
| Additional Paid-In Capital | 1541.02 | 1476.41 | 1399.77 | 1300.72 | 1226.45 |
| Retained Earnings (Accumulated Deficit) | -1557.69 | -1264.03 | -974.011 | -784.72 | -715.827 |
| Other Equity, Total | -5.72 | -4.163 | -4.499 | -0.747 | -2.281 |
| Total Liabilities & Shareholders’ Equity | 610.087 | 773.821 | 826.84 | 857.397 | 880.598 |
| Total Common Shares Outstanding | 94.1661 | 92.881 | 91.441 | 87.657 | 85.432 |
| Total Inventory | 40.436 | 31.015 | 16.53 | 6.887 | |
| Other Current Assets, Total | 4.353 | 5.07 | 1.807 | 1.717 | |
| Current Port. of LT Debt/Capital Leases | 0.036 | 0.011 | 12.33 | 12.351 | |
| Deferred Income Tax | 9.192 | 8.675 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 430.549 | 492.826 | 474.224 | 520.643 | 524.415 |
| Raha ja lühiajalised investeeringud | 355.949 | 422.008 | 408.52 | 438.133 | 428.075 |
| Cash | 145.81 | 135.819 | 104.509 | 128.152 | 165.436 |
| Raha ja ekvivalendid | 42.74 | 19.881 | 51.451 | 39.606 | 20.46 |
| Lühiajalised investeeringud | 167.399 | 266.308 | 252.56 | 270.375 | 242.179 |
| Laekumata arved, neto | 17.654 | 16.299 | 15.328 | 33.573 | 43.883 |
| Accounts Receivable - Trade, Net | 29.217 | 28.387 | 29.665 | 60.352 | 82.638 |
| Total Inventory | 42.456 | 40.436 | 39.95 | 40.899 | 43.067 |
| Prepaid Expenses | 14.49 | 9.73 | 10.426 | 8.038 | 9.39 |
| Other Current Assets, Total | 4.353 | ||||
| Total Assets | 538.544 | 610.087 | 608.837 | 686.789 | 745.934 |
| Property/Plant/Equipment, Total - Net | 95.367 | 100.933 | 105.19 | 109.159 | 114.871 |
| Property/Plant/Equipment, Total - Gross | 253.644 | ||||
| Accumulated Depreciation, Total | -152.711 | ||||
| Long Term Investments | 5.884 | 9.409 | 22.411 | 50.414 | 97.643 |
| Other Long Term Assets, Total | 6.744 | 6.919 | 7.012 | 6.573 | 9.005 |
| Total Current Liabilities | 254.746 | 273.562 | 251.994 | 240.34 | 255.374 |
| Accounts Payable | 71.282 | 30.758 | 19.323 | 29.36 | 36.353 |
| Accrued Expenses | 166.969 | 229.639 | 224.577 | 202.681 | 211.518 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.036 | ||||
| Other Current Liabilities, Total | 16.495 | 13.129 | 8.094 | 8.299 | 7.503 |
| Total Liabilities | 587.396 | 631.534 | 582.531 | 583.009 | 587.886 |
| Total Long Term Debt | 17.276 | 17.054 | 15.422 | 16.439 | 17.374 |
| Long Term Debt | 17.276 | 16.917 | 15.422 | 16.439 | 17.374 |
| Capital Lease Obligations | 0.137 | ||||
| Deferred Income Tax | |||||
| Minority Interest | 19.967 | 19.967 | 19.967 | 19.967 | 19.967 |
| Other Liabilities, Total | 295.407 | 320.951 | 295.148 | 306.263 | 295.171 |
| Total Equity | -48.852 | -21.447 | 26.306 | 103.78 | 158.048 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | |
| Common Stock | 0.966 | 0.942 | 0.939 | 0.937 | 0.933 |
| Additional Paid-In Capital | 1589.15 | 1541.02 | 1524.23 | 1509.64 | 1490.86 |
| Retained Earnings (Accumulated Deficit) | -1634.39 | -1557.69 | -1491.51 | -1399.86 | -1327.24 |
| Other Equity, Total | -4.57 | -5.72 | -7.346 | -6.93 | -6.505 |
| Total Liabilities & Shareholders’ Equity | 538.544 | 610.087 | 608.837 | 686.789 | 745.934 |
| Total Common Shares Outstanding | 96.623 | 94.1661 | 93.936 | 93.733 | 93.289 |
- Aastas
- Kvartalis
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Netotulu/algväärtus | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Raha majandustegevusest | -145.933 | -82.232 | 81.602 | -78.705 | -76.144 |
| Raha majandustegevusest | 10.604 | 14.809 | 22.047 | 21.454 | 6.562 |
| Mittelikviidsed varad | 66.687 | 132.899 | 74.216 | 62.47 | 52.112 |
| Makstud intressid | 0.104 | 0.094 | 0.135 | 0.174 | 0.218 |
| Muutused tööjõus | 70.43 | 60.083 | 174.63 | -85.659 | -48.398 |
| Tulu investeeringutelt | 89.116 | -426.972 | 452.487 | 120.018 | -522.123 |
| Kapitalikulutused | -38.741 | -30.186 | -3.994 | -5.762 | -8.02 |
| Muud rahavood investeeringutelt, kokku | 127.857 | -396.786 | 456.481 | 125.78 | -514.103 |
| Rahavood investeeringutelt | 46.776 | -0.563 | 13.343 | -4.3 | 13.875 |
| Rahavoogudesse investeerimine | -6.62 | -7.372 | -11.463 | -12.75 | -15.612 |
| Aktsiate emiteerimine (tagasiost), neto | 53.934 | 12.701 | 37.829 | 20.778 | 29.847 |
| Laenu väljastamine (kustutamine), neto | -0.538 | -5.892 | -13.023 | -12.328 | -0.36 |
| Muutused valuutakursside kõikumisest | -5.482 | 2.597 | 4.695 | -0.005 | -0.008 |
| Rahaline kogumuutus | -15.523 | -507.17 | 552.127 | 37.008 | -584.4 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -76.705 | -293.654 | -227.479 | -135.829 | -63.205 |
| Cash From Operating Activities | -101.591 | -145.933 | -93.42 | -41.54 | -8.476 |
| Cash From Operating Activities | 2.965 | 10.604 | 7.914 | 5.235 | 2.584 |
| Non-Cash Items | 18.148 | 66.687 | 49.928 | 34.441 | 17.77 |
| Changes in Working Capital | -45.999 | 70.43 | 76.217 | 54.613 | 34.375 |
| Cash From Investing Activities | 103.482 | 89.116 | 88.023 | 43.24 | 25.935 |
| Capital Expenditures | -0.591 | -38.741 | -38.408 | -37.543 | -36.638 |
| Other Investing Cash Flow Items, Total | 104.073 | 127.857 | 126.431 | 80.783 | 62.573 |
| Cash From Financing Activities | 31.485 | 46.776 | -1.898 | -0.806 | -2.893 |
| Financing Cash Flow Items | 0 | -6.62 | -4.562 | -3.361 | -2.974 |
| Issuance (Retirement) of Stock, Net | 31.657 | 53.934 | 2.989 | 2.779 | 0.183 |
| Issuance (Retirement) of Debt, Net | -0.172 | -0.538 | -0.325 | -0.224 | -0.102 |
| Foreign Exchange Effects | -0.526 | -5.482 | -7.968 | -4.359 | 0.107 |
| Net Change in Cash | 32.85 | -15.523 | -15.263 | -3.465 | 14.673 |
| Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
|---|---|---|---|---|---|---|
| PRIMECAP Management Company | Investment Advisor | 14.4767 | 14126697 | 231619 | 2023-03-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 9.0286 | 8810326 | -613439 | 2023-03-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.2737 | 6122003 | 89685 | 2023-03-31 | LOW |
| Astellas Pharma Inc | Corporation | 5.0915 | 4968367 | 0 | 2023-01-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.1772 | 4076167 | -188810 | 2023-03-31 | LOW |
| Point72 Asset Management, L.P. | Hedge Fund | 3.5113 | 3426427 | -1355218 | 2023-03-31 | HIGH |
| First Trust Advisors L.P. | Investment Advisor | 2.7884 | 2720975 | -254678 | 2023-03-31 | LOW |
| Baker Bros. Advisors LP | Hedge Fund | 2.7027 | 2637384 | 1262173 | 2023-03-31 | LOW |
| Armistice Capital LLC | Hedge Fund | 2.3693 | 2312000 | -1552000 | 2023-03-31 | HIGH |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.7703 | 1727545 | 70450 | 2023-03-31 | LOW |
| Two Sigma Investments, LP | Hedge Fund | 1.7676 | 1724909 | 512435 | 2023-03-31 | HIGH |
| Schroder Investment Management North America Inc. | Investment Advisor | 1.5138 | 1477161 | -246616 | 2023-03-31 | LOW |
| Artisan Partners Limited Partnership | Investment Advisor | 1.3847 | 1351230 | 1351230 | 2023-03-31 | LOW |
| Assenagon Asset Management S.A. | Investment Advisor | 1.3779 | 1344583 | 1344583 | 2023-03-31 | HIGH |
| Jacobs Levy Equity Management, Inc. | Investment Advisor/Hedge Fund | 1.1877 | 1159027 | -348288 | 2023-03-31 | MED |
| Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 1.1157 | 1088768 | 593915 | 2023-03-31 | LOW |
| Eventide Asset Management, LLC | Investment Advisor | 0.9838 | 960000 | 960000 | 2023-03-31 | MED |
| Nuveen LLC | Pension Fund | 0.9185 | 896293 | 328958 | 2023-03-31 | LOW |
| Adage Capital Management, L.P. | Hedge Fund | 0.8711 | 850000 | -1800000 | 2023-03-31 | MED |
| Eagle Asset Management, Inc. | Investment Advisor/Hedge Fund | 0.8488 | 828307 | -74825 | 2023-03-31 | LOW |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group535K+
Kauplejad
87K+
Igakuiste aktiivsete klientide arv
$113M+
Igakuine investeerimise maht
$64M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
Kauplemise vahendustasu
0
- 1:1
Finantsvõimendus
1:1
- 20
- 100
- 500
- 1000
- 10000
Investeering
Tehingu suurus (võimendus x investeering):
Avamishind
Close
Lühike Pikk
FibroGen, Inc Company profile
Ettevõttest FibroGen, Inc
FibroGen, Inc. on biofarmatseutiline ettevõte. Ettevõte tegeleb esmaklassiliste ravimite avastamise, arendamise ja turustamisega. Ettevõte rakendab oma võimeid hüpoksia-indutseeritava faktori (HIF) bioloogias, 2-oksoglutaraadi ensütoloogias ja sidekoe kasvufaktori (CTGF) bioloogias, et arendada ravimeid aneemia, fibrootiliste haiguste ja vähi raviks. Ettevõtte toode Roxadustat on suukaudne väikesemolekulaarne HIF-prolüülhüdroksülaasi (HIF-PH) aktiivsuse inhibiitor, mis on mõeldud kroonilisest neeruhaigusest põhjustatud aneemia raviks. Ettevõte arendab Roxadustat'i ka müelodüsplastiliste sündroomide (MDS) aneemia raviks. Ettevõte arendab Roxadustat'i ka keemiaravi poolt põhjustatud aneemia (CIA) raviks. Pamrevlumab, inimese CTGF-vastane monoklonaalne antikeha idiopaatilise kopsufibroosi (IPF), lokaalselt kaugelearenenud opereerimata kõhunäärmevähi (LAPC) ja Duchenne'i lihasdüstroofia (DMD) raviks.
| Industry: | Biotechnology & Medical Research (NEC) |
409 Illinois Street
SAN FRANCISCO
CALIFORNIA 94158
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 535,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com